ClinicalTrials.gg
RecruitingNCT06703710Updated Jan 13, 2025

To Evaluate the Safety/Tolerability and Pharmacokinetic Characteristics in Healthy Volunteers

A Phase 1 interventional study of JW2286 and Placebo of JW2286 in Healthy, sponsored by JW Pharmaceutical. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-13.

Sponsored by JW Pharmaceutical · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Study summary

This clinical trial is a randomized, double-blind, placebo-controlled, single ascending dose, phase 1 clinical trial to evaluate the safety/tolerability and pharmacokinetic characteristics, and to explore food effect and ethnic difference of JW2286 after oral administration in healthy adults.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

JW Pharmaceutical is the lead sponsor of 77 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Korean or Caucasian volunteers

Exclusion criteria

Exclusion Criteria:

  • Individuals with a disease or history
  • Individuals with a history of a gastrointestinal disorder or surgery
  • In the case of all female individuals with , except for those who are surgically sterile
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Test group (JW2286)

    Ethnicity: Korean or Caucasian

    Drug: JW2286

  • Placebo comparator
    Placebo group (Placebo of JW2286)

    Ethnicity: Korean or Caucasian

    Drug: Placebo of JW2286

Interventions

  • DrugJW2286

    a single administration of JW2286 per dose

  • DrugPlacebo of JW2286

    a single administration of Placebo of JW2286 per dose

06

What researchers measure

Primary outcomes

  1. Area under the plasma drug concentration-time curve from 0 to last (AUClast) of JW2286

    Pharmacokinetic Characteristics Evaluation

    Time frame: 0 to 168 hours

  2. Area under the plasma drug concentration-time curve from 0 to infinity (AUCinf) of JW2286

    Pharmacokinetic Characteristics Evaluation

    Time frame: 0 to 168 hours

  3. The maximum or peak concentration between zero and dosing interval (Cmax) of JW2286

    Pharmacokinetic Characteristics Evaluation

    Time frame: 0 to 168 hours

  4. Time of Maximum Concentration (Tmax) of JW2286

    Pharmacokinetic Characteristics Evaluation

    Time frame: 0 to 168 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Nov 2025, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2024
First posted
Nov 25, 2024
StartActual
Jan 6, 2025
Primary completionEst.
Nov 2025
CompletionEst.
Jan 2026
Last update
Jan 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06703710
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Nov 25, 2024
Start date
Jan 6, 2025
Primary completion
Nov 2025 (estimated)
Completion
Jan 2026 (estimated)
Last update
Jan 13, 2025

Study contacts

Hyeona Kim
Contact
hyeona.kim@jwhealthcare.com
+82-840-6791
Soojin Park
Contact
park.soojin@jwhealthcare.com
+82-2-840-6166
SeungHwan Lee
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion